Abstract
Beta-2-microglobulin (β2-MG) and CF.A were measured in the sera of 186 cancer patients divided into two groups: At diagnosis (D) and at follow-up (F). Four groups of patients at diagnosis (D-I, D-II, D-III and D-IV according to TNM classification) and two at follow-up (in remission. F-R S, and in relapse. F-R P) were considered. All patients had normal serum creatinine and urea concentrations. β2-MG values in D-l were significantly (p 100 ng/ml revealed β2-MG values close to those of groups D-I and D-IV. In 10% of patients in stage IV or with CEA > 100 ng/ml β2-MG was lower than the mean value of the healthy population. From data β2-MG is probably produced by an aspecific reaction to the tumor and the decrease in advanced stages could express a decreased immunologic response. On the other hand, high serum β2-MG in the initial stages of the neoplasia may reflect an elevated cell turnover, while low β2-MG during the final stages may be due to a weak expression of the protein by highly undifferentiated cells.
| Original language | English |
|---|---|
| Pages (from-to) | 162-165 |
| Number of pages | 4 |
| Journal | Oncology |
| Volume | 45 |
| Issue number | 3 |
| DOIs | |
| Publication status | Published - 1988 |
Fingerprint
Keywords
- Carcinoembryonic antigen
- Solid tumors
- Tumor marker
- β<inf>2</inf>-Microglobulin
ASJC Scopus subject areas
- Cancer Research
- Oncology
Cite this
Beta-2-microglobulin as a tumor marker in solid malignancies. / Lotzniker, Milvia; Pavesi, Franco; Marbello, Laura; Moratti, Remigio.
In: Oncology, Vol. 45, No. 3, 1988, p. 162-165.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Beta-2-microglobulin as a tumor marker in solid malignancies
AU - Lotzniker, Milvia
AU - Pavesi, Franco
AU - Marbello, Laura
AU - Moratti, Remigio
PY - 1988
Y1 - 1988
N2 - Beta-2-microglobulin (β2-MG) and CF.A were measured in the sera of 186 cancer patients divided into two groups: At diagnosis (D) and at follow-up (F). Four groups of patients at diagnosis (D-I, D-II, D-III and D-IV according to TNM classification) and two at follow-up (in remission. F-R S, and in relapse. F-R P) were considered. All patients had normal serum creatinine and urea concentrations. β2-MG values in D-l were significantly (p 100 ng/ml revealed β2-MG values close to those of groups D-I and D-IV. In 10% of patients in stage IV or with CEA > 100 ng/ml β2-MG was lower than the mean value of the healthy population. From data β2-MG is probably produced by an aspecific reaction to the tumor and the decrease in advanced stages could express a decreased immunologic response. On the other hand, high serum β2-MG in the initial stages of the neoplasia may reflect an elevated cell turnover, while low β2-MG during the final stages may be due to a weak expression of the protein by highly undifferentiated cells.
AB - Beta-2-microglobulin (β2-MG) and CF.A were measured in the sera of 186 cancer patients divided into two groups: At diagnosis (D) and at follow-up (F). Four groups of patients at diagnosis (D-I, D-II, D-III and D-IV according to TNM classification) and two at follow-up (in remission. F-R S, and in relapse. F-R P) were considered. All patients had normal serum creatinine and urea concentrations. β2-MG values in D-l were significantly (p 100 ng/ml revealed β2-MG values close to those of groups D-I and D-IV. In 10% of patients in stage IV or with CEA > 100 ng/ml β2-MG was lower than the mean value of the healthy population. From data β2-MG is probably produced by an aspecific reaction to the tumor and the decrease in advanced stages could express a decreased immunologic response. On the other hand, high serum β2-MG in the initial stages of the neoplasia may reflect an elevated cell turnover, while low β2-MG during the final stages may be due to a weak expression of the protein by highly undifferentiated cells.
KW - Carcinoembryonic antigen
KW - Solid tumors
KW - Tumor marker
KW - β<inf>2</inf>-Microglobulin
UR - http://www.scopus.com/inward/record.url?scp=0023925331&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0023925331&partnerID=8YFLogxK
U2 - 10.1159/000226555
DO - 10.1159/000226555
M3 - Article
C2 - 3285279
AN - SCOPUS:0023925331
VL - 45
SP - 162
EP - 165
JO - Oncology
JF - Oncology
SN - 0030-2414
IS - 3
ER -